Active, not recruitingPhase 1NCT07576010

Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease

Studying Graft versus host disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Daihong Liu
Principal Investigator
Dai-Hong Liu, Dr.
Chinese PLA General Hospital
Intervention
steroids 、ruxolitinib(drug)
Enrollment
30 target
Eligibility
75 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07576010 on ClinicalTrials.gov

Other trials for Graft versus host disease

Additional recruiting or active studies for the same condition.

See all trials for Graft versus host disease

← Back to all trials